April 25, 2020
– AZ, Merck say Lynparza useful in test for mCRPC
AstraZeneca and Merck revealed further positive results from the Phase 3 PROfound trial evaluating LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC).
